Upload
peter-roberts
View
221
Download
1
Tags:
Embed Size (px)
Citation preview
Urology Business
Marc Jablonowski
Area Managers‘ Meeting Q1 2015
Urology Business: Overview
1. An Interesting Market!?2. Our Position in the Market!?3. Lecture Dr. Gutierrez / Q&A 4. ATOMS – Success Stories from Australia5. Support Tools / Business Development
Degree of incontinence following RP
Incontinence after Prostate Surgery(German figures 2014)
75.000 prostate surgeries for BPH | 3% 23.000 rad. prostatectomies | 10%
Annual incidence:3% * 75.000 = 2.25010 % * 23.000 = 2.300
Annual market volume: 4.550
BPH = benign prostatic hyperplasia
4
Artificial Sphincters in Germany
800-900 AMS 800 150 Zephyr ZSI 375
Artificial sphincters: app. 20% of the market
5
France
1100-1200 AUS p.a. in France
6
Market Size in Europe
7
Europe: 500 mln. Inhabitants
8
Marktsize EuropeRegion / Country Inhabitants Implants / mln.
capitaImplant market
Germany 81.000.000 54.9 4450
Austria 8.500.000 41.2 350
Eurozone 335.000.000 25-35 8.375 to 11.725
EU 507.000.000 25-35 12.675 to 17.745
9
>10.000 implantsper year
€ 3000/implant >30 mln. EUR market volume
Is it an interesting market?
An Interesting Market?Boston Scientific‘s Answer is „YES“
A Positive Change in the MarketBoston Scientific acquires a part of AMS
They had a problem!
4.9%7.3%
The Time Plays for A.M.I6 Months of Uncertainty for AMS
The Time Plays for A.M.I6 Months of Uncertainty for AMS
250 employees ???
“Based in Minnetonka, Minn., the AMS Men's Health and Prostate Health businesses include approximately 800 employees worldwide, and generated 2014 sales of approximately $400 million”
March 2, 2015
UncertaintyBoston Scientific / AMS
Employees:– Who will stay in which part of AMS?– Stay in Endo: divestiture expected– Go to Boston Scientific: „Who is synergy?“– Re-organization
Customers:– Who is my future contact?– Which products might be discontinued
(especially female slings and POP)?– What about innovations?
What about Research – Product Innovations?AMS: One Research Center Two Companies
Research and DevelopmentWe are committed to developing new products and improving our current products to provide physicians and patients with better clinical outcomes through less invasive and more efficiently delivered therapies. Most of our research and development activities are conducted in our Minnesota and California facilities, although we also work with physicians, research hospitals, and universities around the world. Many of the ideas for new and improved products come from a global network of leading physicians who also work with us in evaluating new concepts and in conducting clinical trials to gain regulatory approvals. We conduct applied research in areas that we think will likely lead to product commercialization activities.
The Impact on Boston Scientific is Small
Division „Urology and Women‘s Health“ will move up to #4 in sales out of 7 divisions.
The acquisition will increase Boston Scientific turnover by 5-6%
No major impact on Boston Scientific
Is it an interesting market for you?
Overview
1. An Interesting Market!?2. Our Position in the Market!?3. Lecture Dr. Gutierrez / Q&A 4. ATOMS – Success Stories from Australia5. Support Tools / Business Development
Our Position in the Market
Just ask yourself what market share(*) ATOMS should have in your own market?
(*) ATOMS market share among all incontinence implants in your country.
What is the market size?How many ATOMS implants should be sold in your market?
Please write it down for you.
Overview
1. An Interesting Market!?2. Our Position in the Market!?3. Lecture Dr. Gutierrez / Q&A 4. ATOMS – Success Stories from Australia5. Support Tools / Business Development
Overview
1. An Interesting Market!?2. Our Position in the Market!?3. Lecture Dr. Gutierrez / Q&A 4. ATOMS – Success Stories from Australia5. Support Tools / Business Development
Overview
1. An Interesting Market!?2. Our Position in the Market!?3. Lecture Dr. Gutierrez / Q&A 4. ATOMS – Success Stories from Australia5. Support Tools / Business Development
Lecture Dr. MuehlstedtUniversity of Halle, Germany
ATOMS Lecture: University of Halle, Germany
ATOMS 4 Years Data
4 Years Data with ATOMS
53 patients Pre-operative 24 pad Test: 660 ml Irradiated patients: 37% Previous failed therapies:21%
(AMS 800, Argus, AdVance, …)
Success rate: 77% (< 25 ml in 24h)
incl. 49% dry
ATOMS in Comparison with …
MEDICAL TREATMENT SITUATION FOR
MALE URINARY INCONTINENCE IN
GERMANY
German English
HOW ARE MEN MEDICALLY TREATED IN
GERMANY AND WHAT IS THE OUTCOME?
German English
PERFORMED THERAPY
German English
FIRST RESULTS – COMPLICATIONS
German English
FIRST RESULTS - CONTINENCE
FIRST RESULTS – AMS 800 (N=73)
German English
Pads / day
FIRST RESULTS – ADVANCE (N=20)
German English
Pads / day
FIRST RESULTS – ADVANCE XP (N=63)
German English
Pads / day
FIRST RESULTS – ATOMS (N=39)
German English
Pads / day
FIRST RESULTS – ARGUS (N=20)
German English
Pads / day
POST-OPERATIVE PAIN
perineal
inguinal
German English
Very low pain scales for all implants at
max. FU
How Does the Data Compare?
68%
no. 1ATOMS
64%
Argus
52%
AMS 800
49%
AdVanceXP
35%
AdVance
Press Release & Lecture Translated
http://www.pressebox.com/pressrelease/ami-gmbh-agency-for-medical-innovations/ATOMS-4-Years-Results/boxid/731272
Have you heard about …
Male incontinence surgery with an implant
92.3% of patients using zero pads(completely dry – not even a safety pad)
7.7% of patients using only one pad„Following surgery, one patient who previously required two pads was able to use a single pad, which he did not wet each day; he expressed satisfaction with the operation.“
The Germans did well …
… but the Spanish did better
First experience with the ATOMS® implant, a new treatment option for male urinary incontinence
Study size: 13 patients Follow-up: 16 months Pre-OP: 14.4% failed prior incontinence implants
7.7% irradiatedall mild incontinence
Peri-OP surgery time: 86 min.1 hematoma (resolved conservatively)1 retention (resolved, catheter 1 week)3 postoperative perineal–scrotal dysesthesias, resolved spontaneously
Post-OP at max FU 3 patients needed 1 adjustment (2ml)92.3 % completely dry (0 pads)7.7% 1 safety pad
First experience with the ATOMS® implant, a new treatment option for male urinary incontinence
DISCUSSIONAstorbieta et al., in a series of 22 patients, observed full continence or improvement in 90% of the cases [10]. In our study, 92.4% of the patients were fully continent after implantation of this system – this percentage is greater than the figures reported in the aforementioned series. This may be because we only use the ATOMS adjustable implant in patients with mild to moderate UI, not in individuals with severe incontinence.We consider the adjustable systems to be the best option for patients with mild to moderate incontinence. However, considering the difficulties found in divulgating and consolidating widespread use of the Pro Act system, the new ATOMS device – which is based on the same concept since it is adjustable and allows passive continence control with no patient skill of any kind at micturition – might prove accessible to most urologists, since the surgical technique is easy and reproducible.
CONCLUSIONSThe ATOMS adjustable implant offers very good results in treating mild to moderate UI in males. The device is passive and safe, and the implantation technique is easily reproducible. We consider that the implantation of an artificial sphincter in patients of this kind could be disproportionate, considering the degree of incontinence and the cost involved.
Rising EvidenceStudy # Patients
Follow-upPre-OP- irradiated- other failed implants- urine loss
Post-OPSuccess
Comment
Seweryn et al., 2012 38 patients16.9 months [13-21]
radiation: 44.7%failed inc. therapy: 28.9 %6.78 pads/day 747 ml in 24h pad test
success: 84.2%60.5 % dry1.36 pads/day115 ml in 24h pad test
patients following external radiation equal to other patients
Primus, Hoda et al., 2012
99 patients17.8 months [12-33]
rad: 31.3%failed inc. therapy: 34.3 %7.1 pads/day 681 ml in 24h pad test
success: 92%63 % dry1.3 pads/day79.8 ml in 24h pad test
European multi-center
Hoda et al, 2012 124 patients19.1 months [12-36]
rad: 34.5%failed inc. therapy: 36.3 %8.8 pads/day 725 ml in 24h pad test
success: 93,8%61,6 % dry1.8 pads/day
stable results over a period of 3 years, German language
Krause et al., 2014 36 patients30 months [9-52]
rad: 47.2%failed inc. therapy: 30.6 %8.33 pads/day
38.9 % dry (0 or 1 pad)2.77 pads/day30.6 % explantations, therefore many late infections (why ?)
open-access journal,no peer-review, not on PubMed
Gonzalez et al., 2014 13 patients16 months [4-32]
radiation: 7.2 %failed inc. therapy: 14.4 %1.7 pads/day
success: 100%completely dry (0 pads): 92.3%1 pad/day: 7.7%
excellent results for mild incontinence, only 3 patients required 1 adjustment
Muehlstaedt et al., 2015
53 patients26,5 months [3-57]
rad: 37.2%failed inc. therapy: 21 %7.9 pads/day 660 ml in 24h pad test
success: 77 %49 % dry
published in German magazine, no peer-review, not on PubMed
FIRST RESULTS - CONTINENCE
PERFORMED THERAPY
EAU & Competition
AMIAMS
Promedon
Neomedic
ZSI
Bosten Sci.
Coloplast
Bard
Competition
AMS: – Divestiture Prostate Healt end of Q3 to Boston
Scientific– Female Business (slings, POP mesh) unresolved /
laws.
Promedon– Product recall– Customers say: all implants had to be explanted– Cushion ruptures / infections
Competition
Neomedic ZSI
Coloplast
Phorbas
Markets may be partly destroyed for Promedon– Germany– Austria– NL
When will it come back?
Will it come back? … or: what kind of product will come back?
The Two Biggest Competitors are in Trouble
A.M.I. will most likely NEVER again have such a window of opportunity:
– #1 AMS: • Struggling with implants (product recall)• Mesh lawsuits• Company for sale Boston Scientific
– #2 Promedon:• Struggling with implants (product recall)
Coming back to the question
What market share(*) should ATOMS have in your own market?
(*) ATOMS market share among all incontinence implants in your country.
What is the market size?How many ATOMS implants should be sold in your market?
Please lift the appropriate card.
Thank you!